
Erasca Inc reported that its experimental cancer pill shrank tumors in 44% of advanced pancreatic cancer patients during an early-stage trial on Friday. The trial evaluated a 32 mg daily dose of ERAS-0015, targeting mutations that drive tumor growth. The positive response rates offer a new therapeutic avenue for hard-to-treat solid tumors.











